1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 127,00 | 135,00 | 10:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Belite Bio, Inc: Belite Bio to Host Virtual Commercial Day on September 2, 2026 | 3 | GlobeNewswire (USA) | ||
| 14.08. | Benchmark reiterates Belite Bio stock rating on FDA priority review | 2 | Investing.com | ||
| 14.08. | Belite Bio Holds Nearly $780 Million In Cash And U.S. Treasuries Ahead Of Potential Tinlarebant Launch | 4 | pulse2.com | ||
| 14.08. | Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance | 1 | Seeking Alpha | ||
| 13.08. | Earnings Call: Belite Bio übertrifft Gewinnprognose, Aktie gibt dennoch nach | 2 | Investing.com Deutsch | ||
| 13.08. | Full Transcript: Belite Bio Q2 2026 Earnings Call | 3 | Benzinga.com | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 13.08. | Belite Bio reports Q2 results | 1 | Seeking Alpha | ||
| 13.08. | Belite Bio, Inc: Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update | 185 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee... ► Artikel lesen | |
| 12.08. | Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook | 2 | Investing.com | ||
| 12.08. | Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review | 1 | Investing.com | ||
| 12.08. | BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA | 1 | Zacks | ||
| 11.08. | FDA gewährt Belite Bio beschleunigtes Prüfverfahren für Stargardt-Therapie | 1 | Investing.com Deutsch | ||
| 11.08. | Belite Bio, Inc: Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 | 567 | GlobeNewswire (Europe) | Prescription Drug User Fee Act target action date is February 12, 2027If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE... ► Artikel lesen | |
| 11.08. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.08. | Belite Bio, Inc: Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results | 1 | GlobeNewswire (USA) | ||
| 22.07. | Belite Bio stock price target maintained at $200 by H.C. Wainwright | 2 | Investing.com | ||
| 20.07. | Why Is Belite Bio Stock Gaining Monday? | 2 | Benzinga.com | ||
| 20.07. | Belite Bio presents additional Phase 3 trial data for tinlarebant | 4 | Investing.com | ||
| 20.07. | Belite Bio, Inc: Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 | 1 | GlobeNewswire (USA) | ||
| 09.07. | Belite Bio: Phase-3-Daten stützen Zulassungsantrag für Tinlarebant | 5 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| ABIVAX | 97,45 | -0,31 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | -0,40 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| ARGENX | 887,20 | +0,05 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Argenx von 900 auf 925 Euro angehoben, die auf Rekordniveau befindlichen Aktien aber von "Buy" auf "Hold" abgestuft. Es sei... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,268 | -7,59 % | Rendite-Chancen bei Rüstung, Wasserstoff und Green-Tech: Wie sich Deutz, Nel ASA und MustGrow Biologics jetzt für den Befreiungsschlag rüsten! | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Trumps harte Haltung im Iran-Konflikt und die Blockade der Straße von Hormus halten die Finanzmärkte schon seit Wochen und Monaten... ► Artikel lesen | |
| CYTOKINETICS | 62,10 | 0,00 % | If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today | ||
| BEAM THERAPEUTICS | 29,310 | -0,03 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| CYTOMX THERAPEUTICS | 2,875 | +3,27 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| ZAI LAB LTD ADR | 23,000 | +1,77 % | ZAI LAB (09688): 2026 INTERIM REPORT | ||
| CYBIN | 10,580 | +1,54 % | Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board | Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals... ► Artikel lesen | |
| XBIOTECH | 1,928 | 0,00 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen | |
| KYNTRA BIO | 7,000 | +1,45 % | Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,99 % bei einem Aktienkurs von 130,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.